Skip to main content
Erschienen in: Uro-News 3/2020

16.03.2020 | Prostatakarzinom | Fortbildung

Aktuelle Datenlage

Mikronährstoffe beim Prostatakarzinom

verfasst von: Dr. med. Ralph Mücke, Prof. Dr. med. Oliver Micke, Prof. Dr. med. Jens Büntzel

Erschienen in: Uro-News | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Auszug

Um die Lebensqualität während der onkologischen Therapie, aber auch die Prognose beim Prostatakarzinom zu verbessern, gewinnt die Einnahme von Mikronährstoffen zusehens an Bedeutung. Welche Stoffe nachweislich Nutzen bringen und welche im schlimmsten Fall sogar schaden, zeigt dieser Überblick über die Datenlage.
Literatur
1.
Zurück zum Zitat Wien TN et al. Cancer risk with folic acid supplements: A systematic review and meta-analysis. BMJ Open. 2012; 2: e000653. Wien TN et al. Cancer risk with folic acid supplements: A systematic review and meta-analysis. BMJ Open. 2012; 2: e000653.
2.
Zurück zum Zitat Nordström T et al. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate. 2016; 76: 339-48 Nordström T et al. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate. 2016; 76: 339-48
3.
Zurück zum Zitat Margalit DN et al. Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians' Health Study. J Radiat Oncol Biol Phys. 2012; 83: 28-32 Margalit DN et al. Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians' Health Study. J Radiat Oncol Biol Phys. 2012; 83: 28-32
4.
Zurück zum Zitat Ehrenpreis ED et al. A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy. Dis Colon Rectum. 2005; 48:1-8 Ehrenpreis ED et al. A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Retinol Palmitate (Vitamin A) for Symptomatic Chronic Radiation Proctopathy. Dis Colon Rectum. 2005; 48:1-8
5.
Zurück zum Zitat Bai XY et al. Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects. J Cancer. 2015; 6: 913-21 Bai XY et al. Association between Dietary Vitamin C Intake and Risk of Prostate Cancer: A Meta-analysis Involving 103,658 Subjects. J Cancer. 2015; 6: 913-21
6.
Zurück zum Zitat Campbell GD Jr et al. Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med. 1975; 82: 810 Campbell GD Jr et al. Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med. 1975; 82: 810
7.
Zurück zum Zitat Rees DC et al. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ. 1993; 306: 841-2 Rees DC et al. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ. 1993; 306: 841-2
8.
Zurück zum Zitat McCullough ML et al. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr. 2009; 29: 111-32 McCullough ML et al. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr. 2009; 29: 111-32
9.
Zurück zum Zitat Stanaland M et al. Study of the Association Between Serum Vitamin D Levels and Prostate Cancer. Military medicine 2017; 182: e1769-74 Stanaland M et al. Study of the Association Between Serum Vitamin D Levels and Prostate Cancer. Military medicine 2017; 182: e1769-74
10.
Zurück zum Zitat Albanes D et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1850-60 Albanes D et al. Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev. 2011; 20: 1850-60
11.
Zurück zum Zitat Meyer HE et al. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr. 2013; 97: 147-54 Meyer HE et al. Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr. 2013; 97: 147-54
12.
Zurück zum Zitat Gilbert R et al. Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Control. 2012; 23: 575-88 Gilbert R et al. Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Control. 2012; 23: 575-88
13.
Zurück zum Zitat Wagner D et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013; 98: 1498-507 Wagner D et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013; 98: 1498-507
14.
Zurück zum Zitat Nyame YA et al. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol. 2016; 34: 1345-9 Nyame YA et al. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol. 2016; 34: 1345-9
15.
Zurück zum Zitat Mondul AM et al. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival. Cancer epidemiology, biomarkers & prevention. Cancer Epidemiol Biomarkers Prev. 2016; 25: 665-9 Mondul AM et al. Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival. Cancer epidemiology, biomarkers & prevention. Cancer Epidemiol Biomarkers Prev. 2016; 25: 665-9
16.
Zurück zum Zitat Mücke R et al. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe. 2010; 16: 181-6 Mücke R et al. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe. 2010; 16: 181-6
17.
Zurück zum Zitat Bleys J et al. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008; 168: 404-10 Bleys J et al. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008; 168: 404-10
18.
Zurück zum Zitat Lippman SM et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009; 301: 39-51 Lippman SM et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009; 301: 39-51
19.
Zurück zum Zitat Mücke R et al. German Working Group Trace Elements and Electrolytes in Oncology. Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther. 2010; 9: 136-41 Mücke R et al. German Working Group Trace Elements and Electrolytes in Oncology. Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther. 2010; 9: 136-41
20.
Zurück zum Zitat Geybels MS et al. Advanced prostate cancer risk in relation to toenail selenium Levels. J Natl Cancer Inst. 2013; 105: 1394-401 Geybels MS et al. Advanced prostate cancer risk in relation to toenail selenium Levels. J Natl Cancer Inst. 2013; 105: 1394-401
21.
Zurück zum Zitat Kristal AR et al. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. J Natl Cancer Inst. 2014; 106: djt456 Kristal AR et al. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. J Natl Cancer Inst. 2014; 106: djt456
22.
Zurück zum Zitat Kim Y et al. Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis. Anticancer Res. 2015; 35: 4983-96 Kim Y et al. Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis. Anticancer Res. 2015; 35: 4983-96
23.
Zurück zum Zitat Chan JM et al. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016; 25: 1050-8 Chan JM et al. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiol Biomarkers Prev. 2016; 25: 1050-8
24.
Zurück zum Zitat Xie W et al. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. The Prostate. 2016; 76: 691-9 Xie W et al. Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. The Prostate. 2016; 76: 691-9
25.
Zurück zum Zitat Allen NE et al. Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. J Natl Cancer Inst. 2016; https://doi.org/10.1093/jnci/djw153 Allen NE et al. Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies. J Natl Cancer Inst. 2016; https://​doi.​org/​10.​1093/​jnci/​djw153
26.
Zurück zum Zitat Cai X et al. Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression. Sci Rep. 2016; 6: 19213 Cai X et al. Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression. Sci Rep. 2016; 6: 19213
27.
Zurück zum Zitat Outzen M et al. Selenium status and risk of prostate cancer in a Danish population. Br J Nutr. 2016; 115: 1669-77 Outzen M et al. Selenium status and risk of prostate cancer in a Danish population. Br J Nutr. 2016; 115: 1669-77
28.
Zurück zum Zitat Cui Z et al. Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis. Medicine. Feb 2017; 96: e5944. Cui Z et al. Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis. Medicine. Feb 2017; 96: e5944.
29.
Zurück zum Zitat Sayehmiri K et al. The association between Selenium and Prostate Cancer: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2018; 19: 1431-7 Sayehmiri K et al. The association between Selenium and Prostate Cancer: a Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2018; 19: 1431-7
30.
Zurück zum Zitat Kranse R et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer. 2005; 113: 835-40 Kranse R et al. Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer. 2005; 113: 835-40
31.
Zurück zum Zitat Stratton MS et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila). 2010; 3: 1035-43 Stratton MS et al. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila). 2010; 3: 1035-43
32.
Zurück zum Zitat Kenfield SA et al. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst. 2014; 107: 360 Kenfield SA et al. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst. 2014; 107: 360
33.
Zurück zum Zitat Ansong E et al. Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer. PloS one. 2015; 10: e0127295 Ansong E et al. Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer. PloS one. 2015; 10: e0127295
34.
Zurück zum Zitat Meyer F et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005; 116: 182-6 Meyer F et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005; 116: 182-6
35.
Zurück zum Zitat Leitzmann MF et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 2003; 95: 1004-7 Leitzmann MF et al. Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst. 2003; 95: 1004-7
36.
Zurück zum Zitat Zhang Y et al. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control. 2009; 20: 691-8 Zhang Y et al. Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control. 2009; 20: 691-8
Metadaten
Titel
Aktuelle Datenlage
Mikronährstoffe beim Prostatakarzinom
verfasst von
Dr. med. Ralph Mücke
Prof. Dr. med. Oliver Micke
Prof. Dr. med. Jens Büntzel
Publikationsdatum
16.03.2020
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 3/2020
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-020-4059-z

Weitere Artikel der Ausgabe 3/2020

Uro-News 3/2020 Zur Ausgabe

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

LEO Pharma GmbH